Future of MS Management
Key opinion leaders in MS provide closing thoughts on the future of MS treatment including digital therapeutics, new generics, and pipeline drugs on the horizon.
Consensus Guidelines for MS
Thomas Leist, MD and Darin Okuda, MD describe the current landscape of disease guidelines and algorithms in MS treatment.
Disease Progression in MS
Experts in MS discuss the challenges related to treatment selection and management when MS disease progression occurs.
High Efficacy Therapies in MS: Ocrelizumab, Ofatumumab, and Cladribine
Thomas Leist, MD and Darin Okuda, MD discuss clinical trials supporting the use of high efficacy MS therapies: ocrelizumab, ofatumumab, and cladribine.
Generic First Approach in MS
MS specialists Darin Okuda, MD and Thomas Leist, MD discuss the viability of a generic-first treatment approach in MS.
Generic Medications in MS Management
Key opinion leaders in MS describe the impact of generic medication availability on the management of MS and cost of MS treatment.
Risks of Undertreatment in MS and Impact of Early High Efficacy Therapy
Darin Okuda, MD discusses the risk of undertreating MS patients and the avoidance of undertreatment with newer high-efficacy therapies.
Evaluation of MS Outcomes: Patient Clinical Picture
MS specialist Thomas Leist, MD provides insights into the challenges of evaluating and monitoring patients with MS.
Treatment Approach in MS Center of Excellence
Nancy Ross, PharmD, BCACP, MSCS, CSP describes treatment approach and patient navigation in an MS center of excellence.
Payer Management of MS
Maria Lopes, MD, MS discusses payer considerations and challenges in MS treatment management with the ongoing paradigm shift toward early high-efficacy treatment.
Selecting First-Line Therapy in MS
Thomas Leist, MD and Darin Okuda, MD provide insight into first-line treatment selection for MS and the patient factors involved.
Paradigm Shift in MS Management
Experts in MS discuss the evolution in treatment options over time and the shift towards use of early high-efficacy therapy.
Patient Journey in MS
Thomas Leist, MD describes the epidemiology of MS and the journey of patients as the disease progresses.
Overview of Multiple Sclerosis
A multidisciplinary panel of experts provide an overview of the progressive nature of multiple sclerosis (MS) and discuss how clinicians, payers, and pharmacists approach management of the disease.
2 Clarke Drive Cranbury, NJ 08512